MedTrace Logo

Ixazomib + Pomalidomide + Dexamethasone In MM

NCT04094961 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-03-05

No results posted yet for this study

Summary

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Conditions

Interventions

DRUG

Pomalidomide

Oral, administered 14 times per cycle

DRUG

Dexamethasone

Oral, fixed dose administered 8 times per cycle

DRUG

Ixazomib

Oral, administered four times per cycle

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Omar Nadeem, MD

    lead OTHER

Principal Investigators

  • Omar Nadeem, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-18
Primary Completion
2025-06-01
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04094961 on ClinicalTrials.gov